{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:17:39Z","timestamp":1788491859355,"version":"build-2803163510"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-018-1039-7","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T03:18:09Z","timestamp":1547003889000},"page":"125-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options"],"prefix":"10.1007","volume":"79","author":[{"given":"Nicolas","family":"Collongues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Ayme-Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Monassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"issue":"11","key":"1039_CR1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","volume":"84","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165\u201373.","journal-title":"Neurology"},{"issue":"3","key":"1039_CR2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","volume":"63","author":"SJ Pittock","year":"2006","unstructured":"Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63(3):390\u20136.","journal-title":"Arch Neurol"},{"issue":"7","key":"1039_CR3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archneurol.2011.127","volume":"68","author":"N Collongues","year":"2011","unstructured":"Collongues N, Cabre P, Marignier R, Zephir H, Papeix C, Audoin B, et al. A benign form of neuromyelitis optica: does it exist? Arch Neurol. 2011;68(7):918\u201324.","journal-title":"Arch Neurol"},{"issue":"9","key":"1039_CR4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","volume":"74","author":"N Collongues","year":"2010","unstructured":"Collongues N, Marignier R, Zephir H, Papeix C, Blanc F, Ritleng C, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74(9):736\u201342.","journal-title":"Neurology"},{"issue":"9451","key":"1039_CR5","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106\u201312.","journal-title":"Lancet"},{"issue":"4","key":"1039_CR6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473\u20137.","journal-title":"J Exp Med"},{"issue":"24","key":"1039_CR7","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"SR Hinson","year":"2007","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007;69(24):2221\u201331.","journal-title":"Neurology"},{"issue":"11","key":"1039_CR8","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","volume":"205","author":"SR Hinson","year":"2008","unstructured":"Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205(11):2473\u201381.","journal-title":"J Exp Med"},{"issue":"4","key":"1039_CR9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","volume":"109","author":"SR Hinson","year":"2012","unstructured":"Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA. 2012;109(4):1245\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1039_CR10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mcn.2006.09.008","volume":"34","author":"XN Zeng","year":"2007","unstructured":"Zeng XN, Sun XL, Gao L, Fan Y, Ding JH, Hu G. Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes. Mol Cell Neurosci. 2007;34(1):34\u20139.","journal-title":"Mol Cell Neurosci"},{"issue":"5","key":"1039_CR11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/glia.22635","volume":"62","author":"CL Howe","year":"2014","unstructured":"Howe CL, Kaptzan T, Magana SM, Ayers-Ringler JR, LaFrance-Corey RG, Lucchinetti CF. Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia. 2014;62(5):692\u2013708.","journal-title":"Glia"},{"issue":"Pt 7","key":"1039_CR12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain. 2002;125(Pt 7):1450\u201361.","journal-title":"Brain"},{"issue":"Pt 5","key":"1039_CR13","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","volume":"130","author":"T Misu","year":"2007","unstructured":"Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007;130(Pt 5):1224\u201334.","journal-title":"Brain"},{"issue":"9","key":"1039_CR14","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1093\/brain\/awq177","volume":"133","author":"R Marignier","year":"2010","unstructured":"Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain. 2010;133(9):2578\u201391.","journal-title":"Brain"},{"issue":"6","key":"1039_CR15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neurol.2018.02.084","volume":"174","author":"C Alves Do Rego","year":"2018","unstructured":"Alves Do Rego C, Collongues N. Neuromyelitis optica spectrum disorders: features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Rev Neurol (Paris). 2018;174(6):458\u201370.","journal-title":"Rev Neurol (Paris)"},{"issue":"6","key":"1039_CR16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijdevneu.2012.05.004","volume":"30","author":"N Collongues","year":"2012","unstructured":"Collongues N, Chanson JB, Blanc F, Steibel J, Lam CD, Shabbir A, et al. The Brown Norway opticospinal model of demyelination: does it mimic multiple sclerosis or neuromyelitis optica? Int J Dev Neurosci. 2012;30(6):487\u201397.","journal-title":"Int J Dev Neurosci"},{"issue":"4","key":"1039_CR17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1750-3639.1998.tb00194.x","volume":"8","author":"MK Storch","year":"1998","unstructured":"Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998;8(4):681\u201394.","journal-title":"Brain Pathol"},{"issue":"1","key":"1039_CR18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","volume":"14","author":"P Peschl","year":"2017","unstructured":"Peschl P, Schanda K, Zeka B, Given K, Bohm D, Ruprecht K, et al. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflamm. 2017;14(1):208.","journal-title":"J Neuroinflamm"},{"issue":"2","key":"1039_CR19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2051-5960-2-35","volume":"31","author":"S Saadoun","year":"2014","unstructured":"Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun. 2014;31(2):35.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"1039_CR20","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1352458514551455","volume":"21","author":"K Ikeda","year":"2015","unstructured":"Ikeda K, Kiyota N, Kuroda H, Sato DK, Nishiyama S, Takahashi T, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler. 2015;21(5):656\u20139.","journal-title":"Mult Scler"},{"issue":"305","key":"1039_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","volume":"15","author":"L Zhou","year":"2017","unstructured":"Zhou L, Huang Y, Li H, Fan J, Zhangbao J, Yu H, et al. MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J Neuroimmunol. 2017;15(305):19\u201328.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"1039_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jneuroim.2009.07.014","volume":"215","author":"L Sabater","year":"2009","unstructured":"Sabater L, Giralt A, Boronat A, Hankiewicz K, Blanco Y, Llufriu S, et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol. 2009;215(1\u20132):31\u20135.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"1039_CR23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630\u201343.","journal-title":"Ann Neurol"},{"issue":"12","key":"1039_CR24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/ene.12679","volume":"22","author":"R Bernard-Valnet","year":"2015","unstructured":"Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R. Neuromyelitis optica: a positive appraisal of seronegative cases. Eur J Neurol. 2015;22(12):1511\u20131518, e82\u20133.","journal-title":"Eur J Neurol"},{"issue":"9","key":"1039_CR25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1212\/WNL.0b013e318266fc2b","volume":"79","author":"A Vaknin-Dembinsky","year":"2012","unstructured":"Vaknin-Dembinsky A, Brill L, Kassis I, Petrou P, Ovadia H, Ben-Hur T, et al. T-cell reactivity against AQP4 in neuromyelitis optica. Neurology. 2012;79(9):945\u20136.","journal-title":"Neurology"},{"key":"1039_CR26","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264:2088\u201394.","journal-title":"J Neurol"},{"issue":"7","key":"1039_CR27","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","volume":"21","author":"R Hoftberger","year":"2015","unstructured":"Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Calvo AC, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015;21(7):866\u201374.","journal-title":"Mult Scler"},{"issue":"10","key":"1039_CR28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","volume":"88","author":"JW Hyun","year":"2017","unstructured":"Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1039_CR29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617\u201327.","journal-title":"Brain"},{"issue":"8","key":"1039_CR30","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","volume":"20","author":"N Collongues","year":"2014","unstructured":"Collongues N, Marignier R, Jacob A, Leite MI, Siva A, Paul F, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler. 2014;20(8):1086\u201394.","journal-title":"Mult Scler"},{"issue":"12","key":"1039_CR31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79(12):1273\u20137.","journal-title":"Neurology"},{"issue":"4","key":"1039_CR32","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","volume":"1","author":"S Ramanathan","year":"2014","unstructured":"Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e40.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"1039_CR33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.24208","volume":"76","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, de Haidar Jorge FM, Nakashima I, Nishiyama S, Takahashi T, et al. Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. Ann Neurol. 2014;76(2):305\u20139.","journal-title":"Ann Neurol"},{"issue":"3","key":"1039_CR34","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","volume":"3","author":"M Sepulveda","year":"2016","unstructured":"Sepulveda M, Armangue T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e225.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"1039_CR35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","volume":"23","author":"ED van Pelt","year":"2016","unstructured":"van Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol. 2016;23(3):580\u20137.","journal-title":"Eur J Neurol"},{"issue":"21","key":"1039_CR36","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858\u201369.","journal-title":"Neurology"},{"issue":"2","key":"1039_CR37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"6","key":"1039_CR38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","volume":"77","author":"AK Probstel","year":"2011","unstructured":"Probstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;77(6):580\u20138.","journal-title":"Neurology"},{"issue":"2","key":"1039_CR39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1756285611398939","volume":"4","author":"N Collongues","year":"2011","unstructured":"Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord. 2011;4(2):111\u201321.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1039_CR40","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206\u201316.","journal-title":"Ann Neurol"},{"issue":"4","key":"1039_CR41","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S, Merle H, Ferge JL, Mehdaoui H, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346\u201351.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1039_CR42","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2017","unstructured":"Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377\u201384.","journal-title":"Mult Scler"},{"issue":"4","key":"1039_CR43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501\u20134.","journal-title":"Mult Scler"},{"issue":"1","key":"1039_CR44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13(1):280.","journal-title":"J Neuroinflamm"},{"issue":"25","key":"1039_CR45","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","volume":"283","author":"CA Walshe","year":"2008","unstructured":"Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem. 2008;283(25):16971\u201384.","journal-title":"J Biol Chem"},{"issue":"2","key":"1039_CR46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cyto.990140212","volume":"14","author":"LE Hultin","year":"1993","unstructured":"Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14(2):196\u2013204.","journal-title":"Cytometry"},{"issue":"9","key":"1039_CR47","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","volume":"41","author":"T Illidge","year":"2015","unstructured":"Illidge T, Klein C, Sehn LH, Davies A, Salles G, Cartron G. Obinutuzumab in hematologic malignancies: lessons learned to date. Cancer Treat Rev. 2015;41(9):784\u201392.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"1039_CR48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A, Foa R, Gaidano G, Gamba E, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs. 2013;5(6):826\u201337.","journal-title":"mAbs"},{"issue":"9","key":"1039_CR49","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989\u201395.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1039_CR50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","volume":"14","author":"J Boye","year":"2003","unstructured":"Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14(4):520\u201335.","journal-title":"Ann Oncol"},{"issue":"4","key":"1039_CR51","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3109\/10428190109099335","volume":"42","author":"A Harjunpaa","year":"2001","unstructured":"Harjunpaa A, Wiklund T, Collan J, Janes R, Rosenberg J, Lee D, et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma. 2001;42(4):731\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1039_CR52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4161\/mabs.3.2.14239","volume":"3","author":"LA Lampson","year":"2011","unstructured":"Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood\u2013brain barrier. mAbs. 2011;3(2):153\u201360.","journal-title":"mAbs"},{"issue":"7","key":"1039_CR53","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","volume":"22","author":"N Collongues","year":"2016","unstructured":"Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler. 2016;22(7):955\u20139.","journal-title":"Mult Scler"},{"issue":"8","key":"1039_CR54","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"CS Yang","year":"2013","unstructured":"Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. 2013;81(8):710\u20133.","journal-title":"Neurology"},{"issue":"317","key":"1039_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","volume":"15","author":"J Lin","year":"2018","unstructured":"Lin J, Li X, Xue B, Tong Q, Chen Z, Zhu W, et al. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder. J Neuroimmunol. 2018;15(317):1\u20134.","journal-title":"J Neuroimmunol"},{"issue":"10","key":"1039_CR56","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","volume":"58","author":"S Dass","year":"2008","unstructured":"Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2993\u20139.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1039_CR57","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","volume":"76","author":"TT Batchelor","year":"2011","unstructured":"Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76(10):929\u201330.","journal-title":"Neurology"},{"issue":"11","key":"1039_CR58","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342\u20138.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1039_CR59","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225\u201330.","journal-title":"Mult Scler"},{"issue":"7","key":"1039_CR60","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270\u20132.","journal-title":"Neurology"},{"issue":"1\u20132","key":"1039_CR61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","volume":"324","author":"VH Ip","year":"2013","unstructured":"Ip VH, Lau AY, Au LW, Fan FS, Chan AY, Mok VC, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci. 2013;324(1\u20132):38\u20139.","journal-title":"J Neurol Sci"},{"issue":"11","key":"1039_CR62","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443\u20138.","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"1039_CR63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","volume":"317","author":"JW Lindsey","year":"2012","unstructured":"Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS. Variable results after rituximab in neuromyelitis optica. J Neurol Sci. 2012;317(1\u20132):103\u20135.","journal-title":"J Neurol Sci"},{"issue":"15","key":"1039_CR64","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310\u20135.","journal-title":"Neurology"},{"issue":"4","key":"1039_CR65","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","volume":"22","author":"M Radaelli","year":"2016","unstructured":"Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferre L, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016;22(4):511\u20139.","journal-title":"Mult Scler"},{"issue":"10","key":"1039_CR66","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","volume":"262","author":"H Zephir","year":"2015","unstructured":"Zephir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015;262(10):2329\u201335.","journal-title":"J Neurol"},{"issue":"4","key":"1039_CR67","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/NXI.0000000000000046","volume":"1","author":"G Longoni","year":"2014","unstructured":"Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e46.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"1039_CR68","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s10072-015-2368-x","volume":"36","author":"G Olivieri","year":"2015","unstructured":"Olivieri G, Nociti V, Iorio R, Stefanini MC, Losavio FA, Mirabella M, et al. Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder. Neurol Sci. 2015;36(12):2301\u20132.","journal-title":"Neurol Sci"},{"issue":"4","key":"1039_CR69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1006\/cyto.2002.0885","volume":"19","author":"D Miljkovic","year":"2002","unstructured":"Miljkovic D, Samardzic T, Drakulic D, Stosic-Grujicic S, Trajkovic V. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms. Cytokine. 2002;19(4):181\u20136.","journal-title":"Cytokine"},{"issue":"2\u20133","key":"1039_CR70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2\u20133):85\u2013118.","journal-title":"Immunopharmacology"},{"issue":"1","key":"1039_CR71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","volume":"18","author":"Y Jiao","year":"2018","unstructured":"Jiao Y, Cui L, Zhang W, Zhang C, Zhang Y, Zhang X, et al. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study. BMC Neurol. 2018;18(1):47.","journal-title":"BMC Neurol"},{"key":"1039_CR72","first-page":"135245851773013","volume":"1","author":"MA Mealy","year":"2017","unstructured":"Mealy MA, Kim SH, Schmidt F, Lopez R, Jimenez Arango JA, Paul F, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2017;1:1352458517730131.","journal-title":"Mult Scler"},{"issue":"11","key":"1039_CR73","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","volume":"71","author":"SY Huh","year":"2014","unstructured":"Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71(11):1372\u20138.","journal-title":"JAMA Neurol"},{"issue":"9","key":"1039_CR74","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128\u201333.","journal-title":"Arch Neurol"},{"issue":"3","key":"1039_CR75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","volume":"22","author":"IH Jeong","year":"2016","unstructured":"Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22(3):329\u201339.","journal-title":"Mult Scler"},{"issue":"3","key":"1039_CR76","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324\u201330.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1039_CR77","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1046\/j.1365-2036.2001.01102.x","volume":"15","author":"OH Nielsen","year":"2001","unstructured":"Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001;15(11):1699\u2013708.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1039_CR78","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"RN Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE. Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51(4):1219\u201320.","journal-title":"Neurology"},{"issue":"Pt 11","key":"1039_CR79","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(Pt 11):3072\u201380.","journal-title":"Brain"},{"issue":"7","key":"1039_CR80","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659\u201366.","journal-title":"Neurology"},{"issue":"11","key":"1039_CR81","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20(11):1533\u201340.","journal-title":"Mult Scler"},{"key":"1039_CR82","first-page":"135245851877658","volume":"1","author":"DB Bichuetti","year":"2018","unstructured":"Bichuetti DB, Perin MMM, Souza NA, Oliveira EML. Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler. 2018;1:1352458518776584.","journal-title":"Mult Scler"},{"issue":"9","key":"1039_CR83","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003\u20139.","journal-title":"J Neurol"},{"issue":"1","key":"1039_CR84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jns.2004.04.015","volume":"223","author":"O Neuhaus","year":"2004","unstructured":"Neuhaus O, Kieseier BC, Hartung HP. Mechanisms of mitoxantrone in multiple sclerosis\u2014what is known? J Neurol Sci. 2004;223(1):25\u20137.","journal-title":"J Neurol Sci"},{"issue":"7","key":"1039_CR85","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","volume":"63","author":"B Weinstock-Guttman","year":"2006","unstructured":"Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006;63(7):957\u201363.","journal-title":"Arch Neurol"},{"issue":"2","key":"1039_CR86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/1352458502ms790oa","volume":"8","author":"HL Weiner","year":"2002","unstructured":"Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler. 2002;8(2):142\u201354.","journal-title":"Mult Scler"},{"issue":"11","key":"1039_CR87","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","volume":"44","author":"ME de Jonge","year":"2005","unstructured":"de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44(11):1135\u201364.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1039_CR88","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/ncprheum0818","volume":"4","author":"J Birnbaum","year":"2008","unstructured":"Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008;4(7):381\u20136.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"3","key":"1039_CR89","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1191\/096120399678847696","volume":"8","author":"F Bonnet","year":"1999","unstructured":"Bonnet F, Mercie P, Morlat P, Hocke C, Vergnes C, Ellie E, et al. Devic\u2019s neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus. 1999;8(3):244\u20137.","journal-title":"Lupus"},{"issue":"1","key":"1039_CR90","first-page":"172","volume":"35","author":"CC Mok","year":"2008","unstructured":"Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol. 2008;35(1):172\u20134.","journal-title":"J Rheumatol"},{"issue":"4","key":"1039_CR91","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/08830738060210040701","volume":"21","author":"B Arabshahi","year":"2006","unstructured":"Arabshahi B, Pollock AN, Sherry DD, Albert DA, Kreiger PA, Pessler F. Devic disease in a child with primary Sjogren syndrome. J Child Neurol. 2006;21(4):285\u20136.","journal-title":"J Child Neurol"},{"issue":"12","key":"1039_CR92","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/jcm5120107","volume":"5","author":"D Chen","year":"2016","unstructured":"Chen D, Gallagher S, Monson NL, Herbst R, Wang Y. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016;5(12):107.","journal-title":"J Clin Med"},{"key":"1039_CR93","first-page":"135245851774064","volume":"1","author":"MA Agius","year":"2017","unstructured":"Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2017;1:1352458517740641.","journal-title":"Mult Scler"},{"issue":"15","key":"1039_CR94","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","volume":"82","author":"M Araki","year":"2014","unstructured":"Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302\u20136.","journal-title":"Neurology"},{"issue":"7","key":"1039_CR95","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","volume":"72","author":"M Ringelstein","year":"2015","unstructured":"Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756\u201363.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1039_CR96","first-page":"1159","volume":"66","author":"T Yamamura","year":"2014","unstructured":"Yamamura T, Araki M. Use of tocilizumab, an antibody against interleukin-6 receptor, for the treatment of neuromyelitis optica. Brain Nerve. 2014;66(10):1159\u201365.","journal-title":"Brain Nerve"},{"issue":"11","key":"1039_CR97","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","volume":"28","author":"T Igawa","year":"2010","unstructured":"Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28(11):1203\u20137.","journal-title":"Nat Biotechnol"},{"key":"1039_CR98","first-page":"abstract 323","volume":"2018","author":"T Yamamura","year":"2018","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg BM, Zakrzewska-Pniewska B, et al. A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorders (NMOSD). ECTRIMS Congress. 2018;2018:abstract 323.","journal-title":"ECTRIMS Congress"},{"issue":"6","key":"1039_CR99","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554\u201362.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1039_CR100","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41598-017-01087-7","volume":"7","author":"T Fukuzawa","year":"2017","unstructured":"Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017;7(1):1080.","journal-title":"Sci Rep"},{"issue":"6","key":"1039_CR101","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2141.2007.06974.x","volume":"140","author":"C de Romeuf","year":"2008","unstructured":"de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA\/CD16. Br J Haematol. 2008;140(6):635\u201343.","journal-title":"Br J Haematol"},{"issue":"8","key":"1039_CR102","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Investig. 2016;126(8):3036\u201352.","journal-title":"J Clin Investig"},{"issue":"6","key":"1039_CR103","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bpa.12085","volume":"23","author":"AS Verkman","year":"2013","unstructured":"Verkman AS, Phuan PW, Asavapanumas N, Tradtrantip L. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol. 2013;23(6):684\u201395.","journal-title":"Brain Pathol"},{"issue":"3","key":"1039_CR104","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71(3):314\u201322.","journal-title":"Ann Neurol"},{"issue":"5","key":"1039_CR105","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","volume":"26","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Anderson MO, Saadoun S, Phuan PW, Papadopoulos MC, et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J. 2012;26(5):2197\u2013208.","journal-title":"FASEB J"},{"issue":"8","key":"1039_CR106","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","volume":"181","author":"T Vincent","year":"2008","unstructured":"Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood\u2013brain barrier permeability and granulocyte recruitment. J Immunol. 2008;181(8):5730\u20137.","journal-title":"J Immunol"},{"issue":"3","key":"1039_CR107","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","volume":"83","author":"F Shimizu","year":"2012","unstructured":"Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, Koga M, et al. Sera from neuromyelitis optica patients disrupt the blood\u2013brain barrier. J Neurol Neurosurg Psychiatry. 2012;83(3):288\u201397.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1039_CR108","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cen3.12239","volume":"6","author":"MA Mealy","year":"2015","unstructured":"Mealy MA, Shin K, John G, Levy M. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 2015;6(4):413\u20138.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"1","key":"1039_CR109","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","volume":"4","author":"Y Takeshita","year":"2017","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, et al. Effects of neuromyelitis optica-IgG at the blood\u2013brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e311.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"1039_CR110","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/1352458516672015","volume":"23","author":"T Uchida","year":"2017","unstructured":"Uchida T, Mori M, Uzawa A, Masuda H, Muto M, Ohtani R, et al. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood\u2013brain barrier disruption. Mult Scler. 2017;23(8):1072\u201384.","journal-title":"Mult Scler"},{"issue":"4","key":"1039_CR111","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/jnnp-2013-305907","volume":"85","author":"A Tasaki","year":"2014","unstructured":"Tasaki A, Shimizu F, Sano Y, Fujisawa M, Takahashi T, Haruki H, et al. Autocrine MMP-2\/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2014;85(4):419\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1039_CR112","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","volume":"70","author":"H Zhang","year":"2011","unstructured":"Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol. 2011;70(6):943\u201354.","journal-title":"Ann Neurol"},{"issue":"Pt 2","key":"1039_CR113","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133(Pt 2):349\u201361.","journal-title":"Brain"},{"issue":"9665","key":"1039_CR114","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","volume":"373","author":"C Parker","year":"2009","unstructured":"Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009;373(9665):759\u201367.","journal-title":"Lancet"},{"issue":"6","key":"1039_CR115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","volume":"125","author":"PW Phuan","year":"2013","unstructured":"Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, Tradtrantip L, et al. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol. 2013;125(6):829\u201340.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1039_CR116","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0031-6997(24)01437-6","volume":"52","author":"C Caliezi","year":"2000","unstructured":"Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52(1):91\u2013112.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1039_CR117","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1212\/NXI.0000000000000005","volume":"1","author":"M Levy","year":"2014","unstructured":"Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2014;1(1):e5.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"1039_CR118","doi-asserted-by":"crossref","first-page":"e106824","DOI":"10.1371\/journal.pone.0106824","volume":"9","author":"L Tradtrantip","year":"2014","unstructured":"Tradtrantip L, Asavapanumas N, Phuan PW, Verkman AS. Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model. PLoS One. 2014;9(9):e106824.","journal-title":"PLoS One"},{"issue":"2","key":"1039_CR119","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1352458515586084","volume":"22","author":"L Hertwig","year":"2016","unstructured":"Hertwig L, Pache F, Romero-Suarez S, Sturner KH, Borisow N, Behrens J, et al. Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. Mult Scler. 2016;22(2):160\u201373.","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"1039_CR120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306(1\u20132):82\u201390.","journal-title":"J Neurol Sci"},{"issue":"12","key":"1039_CR121","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1177\/1352458512443994","volume":"18","author":"A Jacob","year":"2012","unstructured":"Jacob A, Saadoun S, Kitley J, Leite M, Palace J, Schon F, et al. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence. Mult Scler. 2012;18(12):1801\u20133.","journal-title":"Mult Scler"},{"issue":"3","key":"1039_CR122","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","volume":"71","author":"S Saadoun","year":"2012","unstructured":"Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71(3):323\u201333.","journal-title":"Ann Neurol"},{"key":"1039_CR123","first-page":"621","volume":"10","author":"N Aikawa","year":"2014","unstructured":"Aikawa N, Kawasaki Y. Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome. Ther Clin Risk Manag. 2014;10:621\u20139.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"1039_CR124","doi-asserted-by":"crossref","first-page":"L53","DOI":"10.1152\/ajplung.00298.2014","volume":"309","author":"A Masood","year":"2015","unstructured":"Masood A, Yi M, Belcastro R, Li J, Lopez L, Kantores C, et al. Neutrophil elastase-induced elastin degradation mediates macrophage influx and lung injury in 60% O2-exposed neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2015;309(1):L53\u201362.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"1039_CR125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1352458512440060","volume":"18","author":"K Herges","year":"2012","unstructured":"Herges K, de Jong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ko RM, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler. 2012;18(4):398\u2013408.","journal-title":"Mult Scler"},{"issue":"20","key":"1039_CR126","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1016\/j.bmcl.2015.08.049","volume":"25","author":"F von Nussbaum","year":"2015","unstructured":"von Nussbaum F, Li VM. Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores. Bioorg Med Chem Lett. 2015;25(20):4370\u201381.","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"1039_CR127","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","volume":"123","author":"H Zhang","year":"2013","unstructured":"Zhang H, Verkman AS. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Investig. 2013;123(5):2306\u201316.","journal-title":"J Clin Investig"},{"issue":"8","key":"1039_CR128","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","volume":"74","author":"C Zhang","year":"2017","unstructured":"Zhang C, Tian DC, Yang CS, Han B, Wang J, Yang L, et al. Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol. 2017;74(8):1010\u20132.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1039_CR129","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2\u00a0years. Arch Neurol. 2011;68(11):1412\u201320.","journal-title":"Arch Neurol"},{"issue":"9","key":"1039_CR130","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110\u20137.","journal-title":"JAMA Neurol"},{"issue":"373","key":"1039_CR131","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","volume":"15","author":"M Cohen","year":"2017","unstructured":"Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, et al. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study. J Neurol Sci. 2017;15(373):335\u20138.","journal-title":"J Neurol Sci"},{"issue":"5","key":"1039_CR132","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00007890-200003150-00025","volume":"69","author":"G Opelz","year":"2000","unstructured":"Opelz G, Dohler B. Critical threshold of azathioprine dosage for maintenance immunosuppression in kidney graft recipients. Collaborative Transplant Study. Transplantation. 2000;69(5):818\u201321.","journal-title":"Transplantation"},{"issue":"2","key":"1039_CR133","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","volume":"4","author":"P Valentino","year":"2017","unstructured":"Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study. Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e317.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"1039_CR134","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0961203312467669","volume":"22","author":"JB Chanson","year":"2013","unstructured":"Chanson JB, de Seze J, Eliaou JF, Vincent T. Immunological follow-up of patients with neuromyelitis optica: is there a good biomarker? Lupus. 2013;22(3):229\u201332.","journal-title":"Lupus"},{"key":"1039_CR135","doi-asserted-by":"crossref","first-page":"146219","DOI":"10.1155\/2013\/146219","volume":"2013","author":"JB Chanson","year":"2013","unstructured":"Chanson JB, Alame M, Collongues N, Blanc F, Fleury M, Rudolf G, et al. Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. Clin Dev Immunol. 2013;2013:146219.","journal-title":"Clin Dev Immunol"},{"key":"1039_CR136","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","volume":"8","author":"P Peschl","year":"2017","unstructured":"Peschl P, Bradl M, Hoftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017;8:529.","journal-title":"Front Immunol"},{"key":"1039_CR137","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-94-024-1057-0_16","volume":"969","author":"L Tradtrantip","year":"2017","unstructured":"Tradtrantip L, Jin BJ, Yao X, Anderson MO, Verkman AS. Aquaporin-targeted therapeutics: state-of-the-field. Adv Exp Med Biol. 2017;969:239\u201350.","journal-title":"Adv Exp Med Biol"},{"issue":"193","key":"1039_CR138","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.lfs.2017.10.021","volume":"15","author":"C Wang","year":"2018","unstructured":"Wang C, Yan M, Jiang H, Wang Q, He S, Chen J, et al. Mechanism of aquaporin 4 (AQP 4) up-regulation in rat cerebral edema under hypobaric hypoxia and the preventative effect of puerarin. Life Sci. 2018;15(193):270\u201381.","journal-title":"Life Sci"},{"issue":"9","key":"1039_CR139","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1111\/ejn.13723","volume":"46","author":"MM Salman","year":"2017","unstructured":"Salman MM, Kitchen P, Woodroofe MN, Brown JE, Bill RM, Conner AC, et al. Hypothermia increases aquaporin 4 (AQP4) plasma membrane abundance in human primary cortical astrocytes via a calcium\/transient receptor potential vanilloid 4 (TRPV4)- and calmodulin-mediated mechanism. Eur J Neurosci. 2017;46(9):2542\u20137.","journal-title":"Eur J Neurosci"},{"key":"1039_CR140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7554\/eLife.38689","volume":"7","author":"OF Harraz","year":"2018","unstructured":"Harraz OF, Longden TA, Hill-Eubanks D, Nelson MT. PIP2 depletion promotes TRPV4 channel activity in mouse brain capillary endothelial cells. Elife. 2018;7:7.","journal-title":"Elife"},{"issue":"1","key":"1039_CR141","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","volume":"24","author":"CF Lucchinetti","year":"2014","unstructured":"Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24(1):83\u201397.","journal-title":"Brain Pathol"},{"issue":"2","key":"1039_CR142","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/72256","volume":"6","author":"GT Manley","year":"2000","unstructured":"Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med. 2000;6(2):159\u201363.","journal-title":"Nat Med"},{"issue":"7","key":"1039_CR143","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/jnr.20819","volume":"83","author":"C Ribeiro Mde","year":"2006","unstructured":"Ribeiro Mde C, Hirt L, Bogousslavsky J, Regli L, Badaut J. Time course of aquaporin expression after transient focal cerebral ischemia in mice. J Neurosci Res. 2006;83(7):1231\u201340.","journal-title":"J Neurosci Res"},{"issue":"51","key":"1039_CR144","doi-asserted-by":"crossref","first-page":"20772","DOI":"10.1073\/pnas.1018262108","volume":"108","author":"P Bargiotas","year":"2011","unstructured":"Bargiotas P, Krenz A, Hormuzdi SG, Ridder DA, Herb A, Barakat W, et al. Pannexins in ischemia-induced neurodegeneration. Proc Natl Acad Sci USA. 2011;108(51):20772\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1039_CR145","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11064-013-1212-z","volume":"39","author":"XX Xiong","year":"2014","unstructured":"Xiong XX, Gu LJ, Shen J, Kang XH, Zheng YY, Yue SB, et al. Probenecid protects against transient focal cerebral ischemic injury by inhibiting HMGB1 release and attenuating AQP4 expression in mice. Neurochem Res. 2014;39(1):216\u201324.","journal-title":"Neurochem Res"},{"issue":"12","key":"1039_CR146","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/jcbfm.2015.156","volume":"35","author":"Y Wang","year":"2015","unstructured":"Wang Y, Huang J, Ma Y, Tang G, Liu Y, Chen X, et al. MicroRNA-29b is a therapeutic target in cerebral ischemia associated with aquaporin 4. J Cereb Blood Flow Metab. 2015;35(12):1977\u201384.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"1039_CR147","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s11064-014-1427-7","volume":"39","author":"L He","year":"2014","unstructured":"He L, Zhang X, Wei X, Li Y. Progesterone attenuates aquaporin-4 expression in an astrocyte model of ischemia\/reperfusion. Neurochem Res. 2014;39(11):2251\u201361.","journal-title":"Neurochem Res"},{"issue":"5","key":"1039_CR148","first-page":"390","volume":"16","author":"A Karasu","year":"2010","unstructured":"Karasu A, Aras Y, Sabanci PA, Saglam G, Izgi N, Biltekin B, et al. The effects of protein kinase C activator phorbol dibutyrate on traumatic brain edema and aquaporin-4 expression. Ulus Travma Acil Cerrahi Derg. 2010;16(5):390\u20134.","journal-title":"Ulus Travma Acil Cerrahi Derg"},{"issue":"3","key":"1039_CR149","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.10.010","volume":"27","author":"T Nakano","year":"2018","unstructured":"Nakano T, Nishigami C, Irie K, Shigemori Y, Sano K, Yamashita Y, et al. Goreisan prevents brain edema after cerebral ischemic stroke by inhibiting aquaporin 4 upregulation in mice. J Stroke Cerebrovasc Dis. 2018;27(3):758\u201363.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"6","key":"1039_CR150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1476-9255-6-18","volume":"2","author":"G Penton-Rol","year":"2009","unstructured":"Penton-Rol G, Cervantes-Llanos M, Martinez-Sanchez G, Cabrera-Gomez JA, Valenzuela-Silva CM, Ramirez-Nunez O, et al. TNF-alpha and IL-10 downregulation and marked oxidative stress in neuromyelitis optica. J Inflamm (Lond). 2009;2(6):18.","journal-title":"J Inflamm (Lond)"},{"issue":"5","key":"1039_CR151","doi-asserted-by":"crossref","first-page":"7756","DOI":"10.3892\/mmr.2015.4366","volume":"12","author":"W Li","year":"2015","unstructured":"Li W, Tan C, Liu Y, Liu X, Wang X, Gui Y, et al. Resveratrol ameliorates oxidative stress and inhibits aquaporin 4 expression following rat cerebral ischemia\u2013reperfusion injury. Mol Med Rep. 2015;12(5):7756\u201362.","journal-title":"Mol Med Rep"},{"issue":"4","key":"1039_CR152","doi-asserted-by":"crossref","first-page":"217","DOI":"10.6026\/97320630011217","volume":"11","author":"MK Mazumder","year":"2015","unstructured":"Mazumder MK, Borah A. Piroxicam confer neuroprotection in cerebral ischemia by inhibiting cyclooxygenases, acid- sensing ion channel-1a and aquaporin-4: an in silico comparison with aspirin and nimesulide. Bioinformation. 2015;11(4):217\u201322.","journal-title":"Bioinformation"},{"issue":"9","key":"1039_CR153","doi-asserted-by":"crossref","first-page":"e73481","DOI":"10.1371\/journal.pone.0073481","volume":"8","author":"P Bhattacharya","year":"2013","unstructured":"Bhattacharya P, Pandey AK, Paul S, Patnaik R, Yavagal DR. Aquaporin-4 inhibition mediates piroxicam-induced neuroprotection against focal cerebral ischemia\/reperfusion injury in rodents. PLoS One. 2013;8(9):e73481.","journal-title":"PLoS One"},{"issue":"4","key":"1039_CR154","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3892\/ijmm.2016.2506","volume":"37","author":"JH Chen","year":"2016","unstructured":"Chen JH, Yang LK, Chen L, Wang YH, Wu Y, Jiang BJ, et al. Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of AQP4 expression in rabbits. Int J Mol Med. 2016;37(4):1059\u201366.","journal-title":"Int J Mol Med"},{"issue":"1","key":"1039_CR155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12868-016-0295-2","volume":"17","author":"M Zhang","year":"2016","unstructured":"Zhang M, Cui Z, Cui H, Cao Y, Zhong C, Wang Y. Astaxanthin alleviates cerebral edema by modulating NKCC1 and AQP4 expression after traumatic brain injury in mice. BMC Neurosci. 2016;17(1):60.","journal-title":"BMC Neurosci"},{"issue":"23","key":"1039_CR156","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.12659\/MSM.903855","volume":"8","author":"L Duan","year":"2017","unstructured":"Duan L, Di Q. Acetazolamide suppresses multi-drug resistance-related protein 1 and P-glycoprotein expression by inhibiting aquaporins expression in a mesial temporal epilepsy rat model. Med Sci Monit. 2017;8(23):5818\u201325.","journal-title":"Med Sci Monit"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-018-1039-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1039-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1039-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:12:04Z","timestamp":1744715524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-018-1039-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":156,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1039-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"8 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N. Collongues has received honoraria for consulting or presentation from Biogen Idec, Almirall, Novartis, Merck Serono, LFB, Teva Pharma, Sanofi-Genzyme, and Roche, and is a member of the Editorial Board of the Journal de la Ligue Fran\u00e7aise contre la Scl\u00e9rose en plaques. E. Aylme-Dietrich has no conflict of interest to declare. L. Monassier has no conflict of interest to declare. J. de Seze has received honoraria for consulting or presentation from Biogen Idec, Novartis, Chugai, Merck Serono, LFB, CSL Behring, Teva Pharma, Sanofi-Genzyme, and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}